Chiesi Farmaceutici S.p.A

Company snapshot

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Col

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chiesi Farmaceutici S.p.A. Not investment advice.

• What is Chiesi Farmaceutici S.p.A?

  Chiesi Farmaceutici S.p.A is a pharma organization headquartered in Parma, IT. Primary therapeutic focus areas include COPD (Chronic Obstructive Pulmonary Disease), Uncontrolled Asthma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this

• Is Chiesi Farmaceutici S.p.A publicly traded?

  Chiesi Farmaceutici S.p.A appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chiesi Farmaceutici S.p.A develop or market?

  We link 3 drug profile(s) where Chiesi Farmaceutici S.p.A is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chiesi-farmaceutici-s-p-a#company-drugs.

• What are the latest developments for Chiesi Farmaceutici S.p.A?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chiesi Farmaceutici S.p.A focus on?

  Chiesi Farmaceutici S.p.A focuses on COPD (Chronic Obstructive Pulmonary Disease), Uncontrolled Asthma based on our analysis of their pipeline programs and drug development activities.